Pharmaceutical

AHA 2024: lerodalcibep provides promising results in open-label extension trial, LIBERATE-OLE

At AHA 2024, clinical trial results were presented from the ongoing open-label extension trial, LIBERATE-OLE, involving lerodalcibep.

Nov 19, 2024 - 06:00
AHA 2024: lerodalcibep provides promising results in open-label extension trial, LIBERATE-OLE
At AHA 2024, clinical trial results were presented from the ongoing open-label extension trial, LIBERATE-OLE, involving lerodalcibep.
Read the original article

Tags:

Previous Article

AHA 2024: Plozasiran demonstrates promising Phase III results in FCS adults

Next Article

EMA’s CHMP to approve BMS’ Opdivo for colorectal cancer

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: U.S. to impose inflation penalties on dozens of drugmakers; Supreme Court will decide abortion pill access

STAT+: Pharmalittle: U.S. to impose inflation penalties...

Dec 15, 2023

Vittoria’s CAR-T therapy secures clinical approval amid FDA scrutiny on sector

Vittoria’s CAR-T therapy secures clinical approval amid...

Dec 8, 2023

STAT+: Hospital-insurer tussle in Arizona puts care denials front and center

STAT+: Hospital-insurer tussle in Arizona puts care den...

May 15, 2023